EAST WINDSOR, N.J.--(BUSINESS WIRE)--NexMed, Inc. (Nasdaq: NEXM), a developer of innovative transdermal products based on its proprietary NexACT® drug delivery technology, today announced the presentation of data on NM100060, a topical onychomycosis (nail fungus) investigative drug product, at the 66th Annual Meeting of the American Academy of Dermatology (AAD), in San Antonio from February 1-5, 2008. The presentation is being sponsored by Novartis Pharma AG and NexMed.
